Back to search
Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma trials may be worth asking aboutClinical trial pipeline · Data from ClinicalTrials.gov
See which Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma trials may be worth asking aboutNorth America
Europe
Asia-Pacific
Rest of World
Trials may have sites in multiple countries. Filtering shows any trial with at least one site in the selected country.
Children, adolescents, and young adults (CAYA) with relapsed/refractory (R/R) high-risk ALK+ Anaplastic Large Cell Lymphoma (ALCL) have a low incidence of overa…
This study involves patients with diffuse large B cell lymphoma (DLBCL), natural killer/T-cell lymphoma (NKTL), or classical Hodgkin lymphoma (cHL) (referred to…
The purpose of this study is to test the safety, tolerability, efficacy, and drug levels of BMS-986369 (Golcadomide) in participants with relapsed or refractory…
Prospective, non-randomized, single arm phase II trial with 2 cohorts of ALK+ ALCL treated with nivolumab